543828 — Sudarshan Pharma Industries Income Statement
0.000.00%
- IN₹6.47bn
- IN₹8.16bn
- IN₹5.05bn
- 64
- 32
- 36
- 39
Annual income statement for Sudarshan Pharma Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,934 | 3,571 | 4,613 | 4,635 | 5,050 |
| Cost of Revenue | |||||
| Gross Profit | 141 | 192 | 304 | 411 | 653 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,869 | 3,469 | 4,473 | 4,420 | 4,702 |
| Operating Profit | 64.2 | 102 | 140 | 216 | 349 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 35.7 | 71.9 | 95 | 152 | 216 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 26.7 | 53 | 70.4 | 115 | 160 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 26.7 | 53 | 70.4 | 115 | 160 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 26.7 | 53 | 70.4 | 115 | 160 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.274 | 0.552 | 0.561 | 0.476 | 0.781 |
| Dividends per Share |